Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance

Table 1

Demographic data and clinical characteristics of vitiligo patients with and without itch.

Characteristics	Itch	Nonitch
Age, mean ± SD (years)	46.5 ± 16.0	45.2 ± 16.2	0.519
Gender, (%)			0.601
(i) Male	27 (33.3)	117 (36.4)
(ii) Female	54 (66.7)	204 (63.6)
Onset (years), median (range)	37 (0–72)	36 (1–75)	0.438
Duration of vitiligo (years), median (range)	6 (0–59)	7 (0.83–51)	0.456
Family history of vitiligo, (%)	17 (21.0)	73 (22.7)	0.735
Family history of thyroid and autoimmune disease, (%)	10 (12.4)	40 (12.5)	0.978
Leukotrichia, (%)	38 (46.9)	151 (47.0)	0.984
Body surface area involvement (%), median (range)	3 (0.2–50)	2 (0.1–90)	0.458
Fitzpatrick skin types, (%)			0.521
(i) Type III	13 (16.0)	57 (17.8)
(ii) Type IV	57 (70.4)	234 (72.9)
(iii) Type V	11 (13.6)	30 (9.3)
Type of vitiligo, (%)			0.618
(i) Nonsegmental	63 (77.8)	258 (80.4)
(ii) Segmental	13 (16.0)	51 (15.9)
(iii) Focal	5 (6.2)	12 (3.7)
Initial location, (%)
(i) Head and neck	37 (45.7)	143 (44.6)	0.855
(ii) Trunk	13 (16.1)	17 (5.3)	0.001
(iii) Arms	4 (4.9)	38 (11.8)	0.070
(iv) Hands	17 (21.0)	103 (32.1)	0.051
(v) Legs	9 (11.1)	23 (7.2)	0.241
(vi) Feet	5 (6.2)	12 (3.7)	0.354
Associated diseases, (%)	28 (34.6)	110 (34.3)	0.959
(i) Hyperthyroidism	1 (2.6)	15 (9.6)	0.560
(ii) Hypothyroidism	1 (2.6)	11 (6.7)	0.560
(iii) Diabetes mellitus	3 (3.7)	14 (4.4)	1.000
(iv) Allergic rhinitis/asthma	6 (7.4)	22 (6.9)	0.861
(v) Alopecia areata	1 (1.2)	9 (2.8)	0.368
(vi) Halo nevi	3 (3.7)	19 (5.9)	0.319
Positive results for anti-microsomal antibody	16 (25.4)	75 (30.0)	0.472
Positive results for anti-thyroglobulin antibody	12 (19.5)	49 (19.8)	0.888
Positive results for ANA	30 (45.5)	117 (45.2)	0.967
TSH level			0.216
(i) Low	2 (3.23)	16 (7.31)
(ii) Normal	60 (96.77)	195 (89.04)
(iii) High	0 (0)	8 (3.65)
DLQI, median (range)	7 (0–26)	5 (0–26)	0.001